natgillin/translations-raw huggingface dataset:
A compound, pharmaceutically acceptable salt or pharmaceutically acceptable prodrug, as defined in claim 1, wherein Ar is a phenyl, pyridyl, pyrimidinyl, or fused-bicyclic heteroaryl group substituted on a carbon ring atom at a position ortho to the point of attachment with an Rk substituent. 
Spoj, farmaceutski prihvatljiva sol ili farmaceutski prihvatljiv prolijek, kao što je definirano u zahtjevu 1, pri čemu Ar je fenil, piridil, pirimidinil, ili fuzionirana biciklična heteroaril grupa supstituirana na prstenu ugljikovog atoma na orto poziciji do točke spajanja sa Rk supstituentom.
A compound of Formula (I) as defined in claim 1, wherein: 
Spoj Formule (I) kao što je definirano u zahtjevu 1, pri čemu:
A compound, pharmaceutically acceptable salt or pharmaceutically acceptable prodrug, as defined in claim 33, wherein Ra and Rb are each independently-H; methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, or hexyl; an ethyl or propyl group substituted with an -OC14alkyl or -NRcRd substituent; or a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopropylmethyl, cyclopentylmethyl, aziridinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-1λ6-thiomorpholin-4-yl, or phenyl group unsubstituted or substituted with a -C1-6alkyl, -OC1-4alkyl, or halo substituent. 
Spoj, farmaceutski prihvatljiva sol ili farmaceutski prihvatljiv prolijek, kao što je definirano u zahtjevu 33, pri čemu su Ra i Rb svaki nezavisno -H; metil, etil, propil, izopropil, butil, izobutil, sec-butil, tert-butil, pentil, izopentil, ili heksil; etil ili propil grupa supstituirana sa -OC14alkilom ili -NRcRd supstituentom; ili ciklopropil, ciklobutil, ciklopentil, cikloheksil, cikloheptil, ciklopropilmetil, ciklopentilmetil, aziridinil, pirolidinil, tetrahidrofuranil, piperidinil, tetrahidropiranil, piperazinil, morfolinil, tiomorfolinil, 1,1-diokso-1λ6-tiomorfolin-4-il, ili fenil grupa nesupstituirana ili supstituirana sa -C1-6alkilom, -OC1-4alkilom, ili halo supstituentom.
A compound, pharmaceutically acceptable salt or pharmaceutically acceptable prodrug, as defined in claim 34, wherein Ra and Rb are each independently-H; methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, or hexyl; an ethyl or propyl group substituted with an -OC14alkyl or -NRcRd substituent; or a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopropylmethyl, cyclopentylmethyl, aziridinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-1λ6-thiomorpholin-4-yl, or phenyl group unsubstituted or substituted with a -C1-6alkyl, -OC1-4alkyl, or halo substituent. 
Spoj, farmaceutski prihvatljiva sol ili farmaceutski prihvatljiv prolijek, kao što je definirano u zahtjevu 34, pri čemu su Ra i Rb svaki nezavisno -H; metil, etil, propil, izopropil, butil, izobutil, sec-butil, tert-butil, pentil, izopentil, ili heksil; etil ili propil grupa supstituirana sa –OC14alkilom ili -NRcRd supstituentom; ili ciklopropil, ciklobutil, ciklopentil, cikloheksil, cikloheptil, ciklopropilmetil, ciklopentilmetil, aziridinil, pirolidinil, tetrahidrofuranil, piperidinil, tetrahidropiranil, piperazinil, morfolinil, tiomorfolinil, 1,1-diokso-1λ6-tiomorfolin-4-il, ili fenil grupa nesupstituirana ili supstituirana sa -C1-6alkilom, -OC1-4alkilom, ili halo supstituentom.
A compound, pharmaceutically acceptable salt or pharmaceutically acceptable prodrug, as defined in claim 33, wherein Ra and Rb are each independently -H, methyl, methoxyethyl, cyclopropyl, cyclopropylmethyl, 2-piperidin-1-yl-ethyl, or 2-dimethylamino-ethyl. 
Spoj, farmaceutski prihvatljiva sol ili farmaceutski prihvatljiv prolijek, kao što je definirano u zahtjevu 33, pri čemu su Ra i Rb svaki nezavisno -H, metil, metoksietil, ciklopropil, ciklopropilmetil, 2-piperidin-1-il-etil, ili 2-dimetilamino-etil.
A compound, pharmaceutically acceptable salt or pharmaceutically acceptable prodrug, as defined in claim 33, wherein Ra and Rb taken together with their nitrogen of attachment form an aziridinyl, pyrrolidinyl, piperidinyl, 2-oxo-piperidin-1-yl, piperazinyl, oxo-piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-1λ6-thiomorpholin-4-yl, 1,1-dioxo-1λ6-[1,2]thiazinan-2-yl, or azepanyl group unsubstituted or substituted with a -C1-6alkyl, -OH, or -CO2H substituent. 
Spoj, farmaceutski prihvatljiva sol ili farmaceutski prihvatljiv prolijek, kao što je definirano u zahtjevu 33, pri čemu Ra i Rb uzeti zajedno sa svojim dušikom na koji su vezani formiraju aziridinil, pirolidinil, piperidinil, 2-oksopiperidin-1-il, piperazinil, okso-piperazinil, morfolinil, tiomorfolinil, 1,1-diokso-1λ6-tiomorfolin-4-il, 1,1-diokso-1λ6-[1,2]tiazinan-2-il, ili azepanil grupa nesupstituirana ili supstituirana sa –C1-6alkilom, -OH, ili -CO2H supstituentom.
A compound, pharmaceutically acceptable salt or pharmaceutically acceptable prodrug, as defined in claim 33, wherein Rc and Rd taken together with their nitrogen of attachment form piperidinyl. 
Spoj, farmaceutski prihvatljiva sol ili farmaceutski prihvatljiv prolijek, kao što je definirano u zahtjevu 33, pri čemu Rc i Rd uzeti zajedno sa svojim dušikom na koji su vezani formiraju piperidinil.
A compound, pharmaceutically acceptable salt or pharmaceutically acceptable prodrug, as defined in claim 33, wherein Ar is a phenyl, pyridyl, pyrimidinyl, or fused-bicyclic heteroaryl group substituted on a carbon ring atom at a position ortho to the point of attachment with an Rk substituent. 
Spoj, farmaceutski prihvatljiva sol ili farmaceutski prihvatljiv prolijek, kao što je definirano u zahtjevu 33, pri čemu Ar je fenil, piridil, pirimidinil, ili-fuzionirana biciklična heteroaril grupa supstituirana na atomu ugljikovog prstena na poziciji orto točke spajanja sa Rk supstituentom.
and pharmaceutically acceptable salts thereof. A compound selected from the group consisting of: 
i farmaceutski prihvatljive soli od njih. Spoj izabran iz grupe koju čine:
A pharmaceutical composition for treating a disease, disorder, or medical condition mediated by TRPV1 activity, comprising: 
Farmaceutska kompozicija za liječenje bolesti, poremećaja ili medicinskog stanja posredovanog preko TRPV1 aktivnosti koja sadrži:
an effective amount of an agent selected from the group consisting of the compounds of any one of claims 1-66; and 
efikasnu količinu sredstva izabranu iz grupe koja se sastoji od spoja prema bilo kom od patentnih zahtjeva 1-66; i
A compound according to claim 68, wherein the disease, disorder, or medical condition is pain. 
Spoj prema zahtjevu 68, gdje je bolest, poremećaj ili medicinsko stanje bol.
A compound according to claim 68, wherein the disease, disorder, or medical condition is itch. 
Spoj prema zahtjevu 68, gdje je bolest, poremećaj ili medicinsko stanje svrab.
A compound according to claim 68, wherein the disease, disorder, or medical condition is cough. 
Spoj prema zahtjevu 68, gdje je bolest, poremećaj ili medicinsko stanje kašalj.
A compound according to claim 68, wherein the disease, disorder, or medical condition is asthma. 
Spoj prema zahtjevu 68, gdje je bolest, poremećaj ili medicinsko stanje astma.
A compound according to claim 68, wherein the disease, disorder, or medical condition is inflammatory bowel disease. 
Spoj prema zahtjevu 68, gdje je bolest, poremećaj ili medicinsko stanje upalna bolest crijeva.
Basket (1) according to claim 1 or 2, wherein the first folding (7) is substantially of 90° and the second folding (9) is greater than 90° and lower than 180°. 
Košara (1) u skladu s patentnim zahtjevom 1 ili 2, pri čemu prvi pregib (7) iznosi 90° i drugi pregib (9) je veći od 90°i manji od 180°.
Basket (1) according to any one of the preceding claims, wherein the afore said subsequent rod (2b) is the immediately more internal rod relatively to the afore said most outer horizontal rod (2a), or rather it is the second horizontal rod from the edge. 
Košara (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu je prije navedena sljedeća šipka (2b) prva uvučenija šipka u odnosu na prije navedenu najistureniju vodoravnu šipku, ili je točnije druga vodoravna šipka od ruba.
The capsule (1) according to claim 1, wherein the body (10) has an overall height of 27mm. 
Kapsula (1) u skladu s patentnim zahtjevom 1, naznačena time što tijelo (10) ima ukupnu visinu od 27 mm.
The capsule (1) according to claim 1, wherein the sealing film (11) is made from flexible multilayer film to preserve freshness. 
Kapsula (1) u skladu s patentnim zahtjevom 1, naznačena time što je film za brtvljenje (11) načinjen od fleksibilnog višeslojnog filma kako bi se očuvala svježina.
The capsule (1) according to claim 1, wherein the capsule (1) is used to pack a single dose of Lebanese or Turkish coffee with or without sugar. 
Kapsula (1) u skladu s patentnim zahtjevom 1, naznačena time što se kapsulu (1) upotrebljava za pakiranje jedne doze libanonske ili turske kave, sa ili bez šećera.
The coffee machine in combination with the capsule (1) according to claim 6, wherein the.coffee-pot (5) is arranged so that it can be tilted forwards to serve the beverage into a cup. 
Stroj za kavu u kombinaciji s kapsulom (1) u skladu s patentnim zahtjevom 6, naznačen time što je lonac za kavu (5) tako smješten da se može nagnuti prema naprijed, kako bi se napitak poslužio u šalicu.
An aqueous adjuvant composition comprising: (a) a TLR-4 agonist and a saponin in a liposomal formulation; and (b) a non-ionic isotonicity agent, wherein the concentration of sodium chloride or the ionic strength in the adjuvant composition is less than 100mM. 
Vodeni adjuvantni pripravak, naznačen time što sadrži: (a) agonist TLR-4 i saponin u liposomskoj formulaciji; i (b) neionsko izotonično sredstvo, gdje je koncentracija natrijevog klorida ili ionska jakost u adjuvantnom pripravku je manja od 100 mM.
A mobile station apparatus (200) which is adapted to search a search space for a physical downlink control channel, PDCCH, transmitted by a base station apparatus, the mobile station apparatus comprising: means adapted for performing blind decoding processing for searching the search space for the PDCCH, wherein the search space is defined based on a first mobile station identity, in a case that the mobile station apparatus has the first mobile station identity and a second mobile station identity; means adapted for identifying that the PDCCH is used for dynamic scheduling when the PDCCH includes the first mobile station identity; and 
Uređaj mobilne stanice (200) koji je prilagođen za pretraživanje prostora pretraživanja za kontrolnim kanalom fizičke silazne veze, PDCCH, koji odašilje uređaj bazne stanice, naznačen time da uređaj mobilne stanice sadrži: sredstva podešena za provođenje obrade slijepog dekodiranja radi pretraživanja prostora pretraživanja za PDCCH, pri čemu je prostor pretraživanja definiran na temelju identiteta prve mobilne stanice, u slučaju da uređaj mobilne stanice ima identitet prve mobilne stanice i identitet druge mobilne stanice; sredstva podešena za prepoznavanje da se PDCCH koristi za dinamično raspoređivanje kada PDCCH sadrži identitet prve mobilne stanice; i sredstva podešena za prepoznavanje da se PDCCH koristi za aktiviranje trajnog raspoređivanja kada PDCCH sadrži identitet druge mobilne stanice.
The mobile communication system according to claim 3, wherein the first mobile station identity is C-RNTI, and the second mobile station identity is C-RNTI for persistent scheduling. 
Mobilni komunikacijski sustav prema zahtjevu 3, naznačen time da je identitet prve mobilne stanice C-RNTI, a identitet druge mobilne stanice je C-RNTI radi trajnog raspoređivanja.
A processing method in a mobile station apparatus which searches a search space for a physical downlink control channel, PDCCH, transmitted by a base station apparatus, the processing method comprising: performing blind decoding processing, for searching the search space for the PDCCH, wherein the search space is defined based on a first mobile station identity, in a case that the mobile station apparatus has the first mobile station identity and a second mobile station identity; identifying that the PDCCH is used for dynamic scheduling when the PDCCH includes the first mobile station identity; and 
Postupak obrade u uređaju mobilne stanice koji pretražuje prostor pretraživanja za kontrolnim kanalom fizičke silazne veze, PDCCH, koji prenosi uređaj bazne stanice, naznačen time da postupak obrade sadrži: provođenje obrade slijepog dekodiranja, radi pretraživanja prostora pretraživanja za PDCCH, pri čemu je prostor pretraživanja određen na temelju identiteta prve mobilne stanice, u slučaju da uređaj mobilne stanice ima identitet prve mobilne stanice i identiteta druge mobilne stanice; prepoznavanje da se PDCCH koristi za dinamično raspoređivanje kada PDCCH sadrži identitet prve mobilne stanice; te prepoznavanje da se PDCCH koristi za aktiviranje trajnog raspoređivanja kada PDCCH sadrži identitet druge mobilne stanice.
A base station apparatus which is adapted to transmit, to a mobile station apparatus, a physical downlink control channel, PDCCH, in a search space, the base station apparatus comprising: means adapted for transmitting to the mobile station apparatus, in the search space, the PDCCH including a first mobile station identity or a second mobile station identity, wherein the search space is defined based on the first mobile station identity, in a case that the mobile station apparatus has the first mobile station identity and the second mobile station identity; the PDCCH is used for dynamic scheduling when the PDCCH includes the first mobile station identity; and the PDCCH is used for deactivating persistent scheduling when the PDCCH includes the second mobile station identity, and resource allocation information is a beforehand determined value. 
Uređaj bazne stanice koji je prilagođen za odašiljanje, na uređaj mobilne stanice, kontrolnog kanala fizičke silazne veze, PDCCH, u prostoru pretraživanja, naznačen time da uređaj bazne stanice sadrži: sredstva podešena za odašiljanje na uređaj mobilne stanice, u prostoru pretraživanja, te PDCCH sadrži identitet prve mobilne stanice ili identitet druge mobilne stanice, pri čemu je prostor pretraživanja određen na temelju identiteta prve mobilne stanice, u slučaju da uređaj mobilne stanice ima identitet prve mobilne stanice i identitet druge mobilne stanice; PDCCH se koristi za dinamično raspoređivanje kada PDCCH sadrži identitet prve mobilne stanice; a PDCCH se koristi za aktiviranje trajnog raspoređivanja kada PDCCH sadrži identitet druge mobilne stanice.
the IgE-mediated disorder is selected from the group consisting of: allergic rhinitis, allergic asthma, non-allergic asthma, atopic dermatitis, allergic gastroenteropathy, anaphylaxis, urticaria, food allergies, allergic bronchopulmonary aspergillosis, parasitic diseases, interstitial cystitis, hyper-IgE syndrome, ataxia-telangiectasia, Wiskott-Aldrich syndrome, athymic lymphoplasia, IgE myeloma, graft-versus-host reaction, allergic purpura and rhinosinusitis; and/or 
je poremećaj, koji je posredovan s IgE, odabran iz skupine koju čine: alergijski rinitis, alergijska astma, nealergijska astma, atopički dermatitis, alergijska gastroenteropatija, anafilaksa, urtikarija, alergije na hranu, alergijska bronhopulmonarna aspergiloza, parazitne bolesti, intersticijski cistitis, hiper-IgE-sindrom, ataxia-telangiectasia, sindrom Wiskott-Aldrich, atimična limfoplazija, IgE mijelom, reakcija usatka protiv stanice domaćina i alergijska purpura, i/ili
Control system according to claim 1 or 2, characterized in that the transceivers of the node and the hub have means for wireless data transfer between the node and the hub. 
Sustav nadzora u skladu s patentnim zahtjevom 1 ili 2, karakteriziran na način da primopredajnici čvora i čvorišta imaju sredstva za bežični prijenos podataka između čvora i čvorišta.
Control system according to claim 4, characterized in that the transceivers of the node and the hub have interfaces for a wired network, such as an RS485 network. 
Sustav nadzora u skladu s patentnim zahtjevom 4, karakteriziran na način da primopredajnici čvora i čvorišta imaju sučelja za žičanu mrežu, kao što je RS485 mreža.
Control system according to any previous claim, characterized in that the hub and the server have means (236, 246) for mutual communication via the Internet. 
Sustav nadzora u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakteriziran na način da čvorište i server imaju sredstva (236, 246) za međusobnu komunikaciju putem Interneta.
Control system according to any previous claim, characterized in that the control element (210a-210h) is a sensor, such as a temperature sensor, a humidity sensor, an optical sensor, a CO2 sensor, a motion sensor, another type of presence sensor, or a camera. 
Sustav nadzora u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakteriziran na način da je element nadzora (210a-210h) osjetnik, kao što je osjetnik temperature, osjetnik vlage, optički osjetnik, CO2 osjetnik, osjetnik pokreta, druga vrsta osjetnika prisutnosti, ili kamera.
Control system according to any previous claim, characterized in that the control element (210a-210h) is an actuator, such as a lighting fixture, a heater, an air conditioner, a fan, or multimedia equipment. 
Sustav nadzora u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakteriziran na način da je element nadzora (210a-210h) pobuđivač, kao što je sklop osvjetljenja, grijač, uređaj za klimatizaciju zraka, ventilator, ili multimedijska oprema.
Control system according to any previous claim, characterized in that the control element (210a-210h) is a control panel or an access control terminal. 
Sustav nadzora u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakteriziran na način da je element nadzora (210a-210h) nadzorna ploča ili pristupni nadzorni terminal.
Salt according to claim 5, which is rosuvastatin (-)-1-[(4-chlorophenyl)-phenyl-methyl]piperazinium salt which exhibits a powder x-ray diffraction pattern measured using CuKa-radiation having characteristic peak locations of 3.9, 10.0 and 16.9 ± 0.2 degrees 2θ, preferably 3.9, 10.0, 16.5, 16.9, 20.2 and 23.2 ± 0.2 degrees 2θ, and more preferably exhibits a powder x-ray diffraction pattern substantially as shown in Fig. 3. 
Sol prema zahtjevu 5, naznačena time, da je to rosuvastatin-(-)-1-[(4-klorofenil)-fenil-metil]piperazin-sol koja prikazuje uzorak difrakcije praha X-zraka mjeren uporabom CuKa-radijacije, s mjestima karakterističnih vršnih vrijednosti na 3,9, 10,0 i 16,9 ± 0,2 stupnjeva 2θ, poželjno na 3,9, 10,0, 16,5, 16,9, 20,2 i 23,2 ± 0,2 stupnjeva 2θ, i još bolje pokazuje uzorak difrakcije praha X-zraka uglavnom kako je prikazano na slici 3.
Process according to claim 8, wherein the amine of formula Z is reacted with a compound of formula I wherein R is (C1-C12)alkyl, wherein the amine of formula Z is preferably used in an amount of 1 to 5 equivalents. 
Postupak prema zahtjevu 8, naznačen time, da amin formule Z reagira sa spojem formule I, gdje R je (C1-C12)alkil, pri čemu se amin formule Z poželjno upotrebljava u količini od 1 do 5 ekvivalenata.
Process according to claim 9, wherein the reaction is carried out in a mixture of organic solvent and water, particularly in a ratio of 10:1 to 1:10, preferably 8:1 to 1:3, more preferably 5:1 to 1:1, most preferably 4:1 to 2:1, wherein the organic solvent is preferably selected from acetonitrile, acetone, methanol, ethanol, isopropanol and mixtures thereof. 
Postupak prema zahtjevu 9, naznačen time, da se reakcija provodi u mješavini organskog otapala i vode, posebno u omjeru od 10:1 do 1:10, poželjno od 8:1 do 1:3, još bolje od 5:1 do 1:1, najbolje od 4:1 do 2:1, pri čemu je organsko otapalo poželjno odabrano od acetonitrila, acetona, metanola, etanola, izopropanola i njihovih mješavina.
Process according to claim 12, wherein the salt of formula VII is first converted to a corresponding alkaline metal salt, particularly the sodium salt, which is subsequently converted to the pharmaceutically acceptable salt of rosuvastatin. 
Postupak prema zahtjevu 12, naznačen time, da se sol formule VII prvo pretvara u odgovarajuću sol alkalijskog metala, posebno u natrijevu sol, koja se uzastopno pretvara u farmaceutski prihvatljivu sol rosuvastatina.
Process according to claim 14 or 15, wherein the at least one solvent is selected from alcohols, ketones, esters and ethers, and preferably selected from isopropyl acetate and tert-butyl methyl ether. 
Postupak prema zahtjevu 14 ili 15, naznačen time, da barem jedno otapalo je odabrano od alkohola, ketona, estera i etera, i poželjno je odabrano od izopropil acetata i tert-butil metiletera.
stirring the suspension at a temperature of 5 to 25 °C, preferably 10 to 15 °C for 30 min to 2 hours, preferably 30 min to 1 hour, such as about 45 min; and 
miješanje suspenzije na temperaturi od 5 do 25°C, poželjno od 10 do 15°C za vrijeme od 30 min do 2 sata, poželjno od 30 min do 1 sata, naime oko 45 min; i
recovering rosuvastatin calcium by filtration. 
obnavljanje rosuvastatin kalcija filtracijom.
said netupitant or a pharmaceutically acceptable salt thereof is administered to said patient on day one, in a therapeutically effective amount which is effective to treat nausea and vomiting during the acute and delayed phases of emesis, and which enters the systemic circulation, crosses the blood brain barrier and occupies at least 70% of NK1 receptors in the striatum seventy-two hours after said administration; 
navedeni netupitant ili njegova farmaceutski prihvatljiva sol je primjenjena na navedenog pacijenta na dan jedan, u terapeutski efikasnoj količini koja je efikasna za liječenje mučnine i povraćanja u toku akutnih i odloženih faza emezisa, i koja ulazi u sustavnu cirkulaciju, prelazi krvno moždanu barijeru i zauzima najmanje 70% NK1 receptora u strijatu sedamdeset i dva sata poslije navedene primjene;
dexamethasone is administered to said patient on day one in a first dose which is ineffective against nausea and vomiting when administered alone, but effective against nausea and vomiting when administered in combination with said netupitant, wherein said first dose comprises from 50 to 70% of a minimum effective dose when administered alone. 
deksametazon se primjenjuje na navedenog pacijenta na dan jedan u prvoj dozi koja je neefikasna protiv mučnine i povraćanja kada se primjenjuje pojedinačno, ali efikasna protiv mučnine i povraćanja kada se primjenjuje u kombinaciji sa navedenim netupitantom, pri čemu navedena prva doza sadrži od 50 do 70% minimalne efikasne doze kada se primjenjuje pojedinačno.
The combination for use according to claim 1 or 2, wherein said netupitant occupies at least 80% of NK1 receptors in the striatum seventy-two hours after said administration. 
Kombinacija za uporabu prema patentnom zahtjevu 1 ili 2, naznačena time što navedeni netupitant zauzima najmanje 80% NK1 receptora u strijatu sedamdeset i dva sata poslije navedene primjene.
The combination for use according to any one of claims 1 to 10, wherein said therapeutically effective amount of 5-HT3 antagonist comprises from about 0.25 to about 0.75 mg. of palonosetron or a pharmaceutically acceptable salt thereof. 
Kombinacija za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačena time što navedena terapeutski efikasna količina 5-HT3 antagonista sadrži od oko 0.25 do oko 0.75 mg palonosetrona ili njegove farmaceutski prihvatljive soli.
about 300 mg. of netupitant as a free base on day one; 
oko 300 mg netupitanta kao slobodna baza na dan jedan;
about 0.56 mg. of palonosetron hydrochloride, corresponding to about 0.5 mg of palonosetron as a free base, on day one; and 
oko 0.56 mg palonosetron hidroklorida, što odgovara oko 0.5 mg palonosetrona kao slobodna baza, na dan jedan; i
about 0.56 mg. of palonosetron hydrochloride (corresponding to about 0.5 mg of palonosetron as a free base) on day one; 
oko 0.56 mg palonosetron hidroklorida (odgovara oko 0.5 mg palonosetrona kao slobodna baza) na dan jedan;
about 8 mg. of dexamethasone on days two, three and four. 
oko 8 mg deksametazona na dane dva, tri i četiri.